FDA approves Lilly's Jaypirca as first-line CLL therapy

Eli Lilly's Jaypirca (pirtobrutinib) received FDA approval for first-line treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma, expanding its label beyond relapsed/refractory settings. This marks a significant label expansion that could reshape the CLL treatment landscape, competing with established BTK inhibitors. The approval is based on clinical trial data, though specific efficacy details are not provided in the source.